CoChat

Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?

Richardson, Kylie, Baillie, Andrew, Reid, Sophie, Morley, Kirsten, Teesson, Maree, Sannibale, Claudia, Weltman, Martin, Haber, Paul · 2008 · Addiction
Cited by 72

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Aim To explore the effect of acamprosate and naltrexone on craving and alcohol consumption in the treatment of alcohol dependence. Design A randomized, double‐blind, single‐dummy, placebo‐controlled trial. Setting Three treatment centres in Sydney, Australia. Participants A total of 169 alcohol‐dependent subjects were given naltrexone (50 mg/day), acamprosate (1998 mg/day) or placebo for 12 weeks, in conjunction with manualized medication compliance therapy. Intervention During the course of the trial, participants kept a daily diary which included the number of standard drinks they consumed and their peak craving for alcohol that day rated on a 0–10 scale. Measurements Subjective ratings of daily craving and daily drinking for the first 6 weeks of treatment. Findings Mixed/hierarchical linear models were employed on an intention‐to‐treat basis. Analyses revealed that craving was a significant predictor of daily drinking and baseline levels of depression were the best predictor of daily craving. There was no significant improvement in model fit when treatment group was added both in models of daily craving and daily drinking. Daily alcohol consumption was best predicted by a model incorporating baseline dependence and depression scores, and daily craving, entered as a time‐varying covariate. However, there was a significant craving × time × treatment interaction (t = −3.365, df = 4413.712, P < 0.001), suggesting that at higher levels of craving drinking was reduced at a significantly greater rate with naltrexone compared to acamprosate. Conclusions Naltrexone had a greater effect on drinking when craving was high. These results support the role of naltrexone in reducing craving when that craving is highly salient. The role of acamprosate in reducing craving was not supported by these findings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1360-0443.2008.02215.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 72

Metadata

Authors
Richardson, K., Baillie, A., Reid, S., Morley, K., Teesson, M., Sannibale, C., Weltman, M., & Haber, P.
Venue
Addiction
Publisher
Wiley
Published
2008-06
Volume
103
Issue
6
Pages
953-959
ISSN
  • 0965-2140 (ISSN-L)
  • 1360-0443
OpenAlex
W2066880844
Cited by
72
References
3
FWCI
3.50
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? https://app.cochat.ai/papers/10.1111/j.1360-0443.2008.02215.x
The paper
Richardson, K., Baillie, A., Reid, S., Morley, K., Teesson, M., Sannibale, C., Weltman, M., & Haber, P. (2008). Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? Addiction. https://doi.org/10.1111/j.1360-0443.2008.02215.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.